Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial

TL;DR: Experts' opinion has changed the attitude to CYC as an anchor drug in the management of severe SSc and it has been pushed to the second and even third treatment option after mycophenolate mofetil, tocilizumab or rituximab.

TL;DR: The clinical features of the pleuropulmonary complications of CTD are described, focusing on their screening, diagnosis and monitoring, and joint management by respiratory and rheumatology paediatricians is recommended.

TL;DR: Describing data about safety and effects in functional decline were obtained from patients in which nintedanib was initiated as an off-label treatment use at the same time they started lung transplant evaluation, and it was hypothesized that patients with severe progressive fibrotic SScILD that were evaluated for lung transplant could also benefit from nintinganib treatment.

TL;DR: There are grounds for hope that better therapeutic options will be available in the near future, and the body of evidence for the efficacy of immunomodulatory approaches is increasing, and now at least one hopeful substance that may directly interfere with fibrosis is being tested.

TL;DR: A multicenter, ongoing study of early-diagnosed cases of systemic sclerosis and comparison patients with systemic lupus erythematosus, polymyositis/dermatomyositis, and Raynaud's phenomenon was conducted in order to develop classification criteria for systemic sclerosis.

TL;DR: Hankinson and Odencrantz as mentioned in this paper used a piecewise polynomial model with age and height as predictors to derive reference values for three race/ethnic groups and should prove useful for diagnostic and research purposes.

TL;DR: Proposed classification criteria for systemic sclerosis had a 97% sensitivity for definite systemic sclerosis and 98% specificity when applied to the case and comparison patients included in this study.